Medium-term Group guidance ahead of US site visit

RNS Number : 8570I

Hikma Pharmaceuticals Plc

15 May 2025

Hikma announces strong medium-term Group guidance ahead of its US site visit

London, 15 May 2025 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, is today hosting sell-side analysts and investors at its US manufacturing and R&D facility in Columbus, Ohio. The senior leadership teams from our Generics and Injectables segments will present on their respective businesses, strategies, and plans to deliver long-term, sustainable growth.

Attendees will tour the Group's state-of-the-art, 1,000,000 sq. ft. facility in Columbus, which produces oral, respiratory and other generic and specialty products. It is one of Hikma's four US manufacturing facilities producing a broad range of medicines for patients across the US, where Hikma is one of the largest suppliers of generic medicines. Attendees will also tour the Company's newly acquired Injectables facility in Bedford, Ohio.

Alongside the event, Hikma is introducing the following medium-term guidance:

· Group revenue growth - 6% to 8% three-year CAGR (2024 to 2027)

· Group core operating profit growth - 7% to 9% three-year CAGR (2024 to 2027)

In addition, Hikma is introducing a five-year target for Group revenue to reach $5 billion by 2030.

Hikma is also announcing that its Generics business is being renamed Hikma Rx to reflect its focus on providing differentiated and complex prescription (Rx) medicines.

The presentation is available on Hikma's website at https://www.hikma.com/investors/results-and-presentations/. A recording and transcript of the presentation and Q&A will be made available following the event.

- ENDS -

Enquiries:

Hikma (Investors)

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050

Guy Featherstone

Director, Investor Relations

+44 (0)20 3892 4389/ +44 7795 896738

Layan Kalisse

Senior Associate, Investor Relations

+44 (0)20 7399 2788/ +44 7970 709912

FTI Consulting (media)

Ciara Martin +44 (0)7779 775979

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAESSFLFSEFA